Successful Use of Sugammadex in a Myasthenic Patient Case Report

Silvia Kangassu Rios, Daiana Gomes, Marcos Lopes De Miranda, Carlos Frederico La Cava, Carlos Darcy Bersot

Department of Anesthesia, Hospital Federal da Lagoa, Rio de Janeiro, Brazil.

DOI: 10.4236/ojanes.2013.31013                

Abstract

The Myasthenia gravis (MG) is an autoimmune disease that affects neuromuscular transmission and leads to a large variation of sensibility on depolarizing and nondepolarizing neuromuscular blocking drugs. Sugammadex is a new drug with the capability to successfully revert the nondepolarizing neuromuscular blocking. This case report will show a patient with MG that was scheduled for thymectomy, with the objective to use sugammadex to reverse a rocuronium induced deep level of neuromuscular block and observing the safe use of sugammadex without complications.

Keywords

Sugammadex; Myasthenia Gravis; Rocuronium; Neuromuscular Monitoring; Anesthesia

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	L. H. Phillips II, “The Epidemiology of Myasthenia Gravis,” Annals of the New York Academy of Sciences, Vol. 998, No. 1, 2006, pp. 407-412.
[2]	K. Osserman and G. Genkins, “Studies in Myasthenia Gravis—Review of a 20-Year Eperience in over 1200 Patients,” Mount Sinai Journal of Medicine, Vol. 38, No. 6, 1971, pp. 497-537.
[3]	S. J. A. Gold and N. J. N. Harper, “The Place of Sugammadex in Anaesthesia Practice,” Trends in Anaesthesia and Critical Care, Vol. 2, No. 1, 2012, pp. 4-9.
[4]	F. X. Dillon, “Anesthesia Issues in the Perioperative Management of Myas-Thenia Gravis,” Seminars in Neurology, Vol. 24, No. 1, 2004, pp. 83-94. doi:10.1055/s-2004-829587
[5]	X. Combes, L. Andriamidy, E. Dufresne, P. Suen, S. Sauvat, E. Scherrer, P. Feiss, J. Marty and P. Duvaldestin, “Comparison of Two Induction Regimens Using or Not Using Muscle Relaxant: Impact on Postoperative Upper Airway Discomfort,” British Journal of Anaesthesia, Vol. 99, No. 2, 2007, pp. 276-281. doi:10.1093/bja/aem147
[6]	P. Duvaldestin, K. Kuizenga, V. Saldien, C. Claudius, F. Servin, J. Klein, B. Debaene and M. Heeringa, “A Randomized, Dose-Response Study of Sugam-Madex Given for the Reversal of Deep Rocuronium or Vecuronium Induced Neuromuscular Blockade under Sevourane Anesthesia,” Anesthesia and Analgesia, Vol. 110, No. 1, 2010, pp. 74-82. doi:10.1213/ANE.0b013e3181c3be3c
[7]	A. Abrishami, J. Ho, J. Wong, L. Yin and F. Chung, Sugammadex, “A Selective Reversal Medication for Preventing Postoperative Residual Neuromuscular Blockade,” Anasthesia & Analgesia, Vol. 110, 2010, p. 1239.
[8]	A. J. Aho, K. Kamata, A. Yli-Hankala, L. P. Lyytikinen, A. Kulkas and V. Jntti, “Elevated Bis and Entropy Values after Sugammadex or Neostig-Mine: An Electroencephalographic or Electromyographic Phenomenon?” Acta Anaesthesiologica Scandinavica, Vol. 56, No. 4, 2012, pp. 465-473. doi:10.1111/j.1399-6576.2011.02647.x